Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens

International Journal of Biological Markers

Volumn 30, Issue 3, 2015, Pages e301-e314

  Zwenger, Ariel O ^a,b   Grosman, Gabriel ^a   Iturbe, Julian ^a,b   Leone, Julieta ^a,b   Vallejo, Carlos T ^b   Leone, José P ^b,c   Verdera, Palmira Pérez ^a,b   Pérez, Juan E ^b   Leone, Bernardo A ^b  

^a Hospital Provincial de Neuquén E Castro Rendón   (Argentina)

^b Oncologic Cooperative Southern Group   (Argentina)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; ERCC1; Predictive factors; Prognostic factors; TUBB3

Indexed keywords

BETA TUBULIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IFOSFAMIDE; MESNA; MONOCLONAL ANTIBODY; NAVELBINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUBB3 PROTEIN, HUMAN; TUBULIN; TUMOR PROTEIN; VINBLASTINE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PROGNOSIS; CERVICAL SQUAMOUS CELL CANCER; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UTERINE CERVIX CARCINOMA; ADJUVANT RADIOTHERAPY; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DISEASE COURSE; GENE EXPRESSION REGULATION; HYSTERECTOMY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYSTERECTOMY; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MESNA; MIDDLE AGED; NEOPLASM PROTEINS; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TUBULIN; UTERINE CERVICAL NEOPLASMS; VINBLASTINE;

EID: 84937875286     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000161     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;(1):CD008285.
3. Lacava JA, Leone BA, Machiavelli M, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol. 1997;15(2):604-609.
4. Vallejo CT, Machiavelli MR, Pérez JE, et al. Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma. Am J Clin Oncol. 2003;26(5):477-482.
5. Vallejo CT, Pérez JE, Domínguez ME, et al. Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix. Am J Clin Oncol. 2000;23(5):481-486.
6. Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23(18):4137-4145.
7. Lissoni AA, Colombo N, Pellegrino A, et al. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a threedrug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol. 2009;20(4):660-665.
8. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004;92(3):801-805.
9. Alvarez EA, Wolfson AH, Pearson JM, et al. A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecol Oncol. 2009;113(2):195-199.
10. Vrdoljak E, Omrcen T, Novaković ZS, et al. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix: final results of a prospective phase II-study. Gynecol Oncol. 2006;103(2): 494-499.
11. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para- aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007;106(2):362-369.
12. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie. 2004;27(1):83-90.
13. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33(6):565-577.
14. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28(16):5082-5092.
15. Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99(1):167-172.
16. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44(1):54-60.
17. Park JS, Jeon EK, Chun SH, et al. ERCC1 (excision repair crosscomplementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecol Oncol. 2011;120(2):275-279.
18. Doll CM, Aquino-Parsons C, Pintilie M, et al. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. Int J Radiat Oncol Biol Phys. 2013;85(3):721-727.
19. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005; 11(1):298-305.
20. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 2005;92(2):E25-E30.
21. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3′ flanking region. Gene. 2008;409(1-2):100-108.
22. McCarroll JA, Gan PP, Liu M, Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 2010; 70(12):4995-5003.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
24. Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012; 7(1):249-256.
25. Hwang JE, Hong JY, Kim K, et al. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer. 2013;13(1):431.
26. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284):781-786.
27. Klopp AH, Eifel PJ. Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol. 2012;22(2): 143-150.
28. Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma. Int J Gynecol Cancer. 2011;21(8): 1479-1485.
29. Liang ZL, Song EK, Ko YB, et al. Excision repair crosscomplementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy. Histopathology. 2011; 59(3):564-567.
30. Bai ZL, Wang YY, Zhe H, He JL, Hai P. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol. 2012;7(1):221.
31. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repairbased personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39(7-8): 1318-1328.
32. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):1022-1030.
33. Hafer K, Iwamoto KS, Scuric Z, Schiestl RH. Adaptive response to gamma radiation in mammalian cells proficient and deficient in components of nucleotide excision repair. Radiat Res. 2007;168(2):168-174.
34. Murray D, Rosenberg E. The importance of the ERCC1/ ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res. 1996;364(3):217-226.
35. Vaezi A, Feldman CH, Niedernhofer LJ. ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmacogenomics Pers Med. 2011;4:47-63.
36. Mehra R, Zhu F, Yang DH, et al. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013; 19(23):6633-6643.
37. Muallem MZ, Marnitz S, Richter R, Köhler C, Sehouli J, Arsenic R. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Anticancer Res. 2014;34(1):401-406.
38. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007;67(19):9356-9363.
39. Ferrandina G, Martinelli E, Zannoni GF, et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol. 2007;104(2):326-330.
40. Teicher BA. Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol. 2009;77(11):1665-1673.